Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients.

Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients. Abstract Text:

Sarah A Cross,Caroline M Perry,Sarah A Cross,Caroline M Perry,

Tacrolimus once-daily (OD) is a new oral formulation of the well established immunosuppressant tacrolimus. Tacrolimus OD provided equivalent steady-state systemic tacrolimus exposure to that achieved with standard oral tacrolimus twice daily in stable renal and liver transplant recipients. The two formulations also provided broadly similar steady-state systemic exposure in de novo renal and liver transplant recipients. In a large, randomised, nonblind, multicentre, three-armed, noninferiority trial in de novo renal transplant recipients, the efficacy failure rates (primary endpoint) [any patient who died, experienced graft failure, had a biopsy-confirmed acute rejection or was lost to follow-up] of tacrolimus OD (14.0%) and standard tacrolimus (15.1%) were noninferior to that of ciclosporin (cyclosporine) microemulsion (17.0%) at 1 year, when each was given in conjunction with corticosteroids, mycophenolate mofetil and basiliximab induction. Data from a pharmacokinetic study suggests that tacrolimus OD has similar efficacy to standard tacrolimus in de novo liver transplant recipients over 6 weeks of treatment. In noncomparative 2-year trials, tacrolimus OD was effective in stable renal and liver transplant recipients converted to tacrolimus OD from standard tacrolimus. The overall tolerability profile of tacrolimus OD appears to be similar to that of standard tacrolimus in de novo and stable renal and liver transplant patients.

Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients. Publishing Authors By Initials

SA Cross,CM Perry,SA Cross,CM Perry,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients. Journal Published:

PUBLICATION TYPE: Review

Journal: Drugs

VOLUME: 67

Page Numbers: 1931-43

Journal Abbreviation: Drugs

ISSN: 0012-6667

DAY: 28

MONTH: 08

YEAR: 2007

Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients. Information

Number of References: 33

LANGUAGE: eng

NlmUniqueID: 7600076

Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients.

AFFILIATION: Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients Related Publications

• "Stay away from them until you're old enough to make a decision": tobacco company testimony about youth smoking initiation.
• 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases.
• A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor.
• Adults with autism show increased sensitivity to outcomes at low error rates during decision-making.
• Balanced production of ribosomal proteins.
• Bias, benefit, or both: evaluating new glioma therapies.
• Comparison of two methods for measuring tongue pressure during swallowing in people with head and neck cancer.
• Congenital glioblastoma: a clinicopathologic and genetic analysis.
• Constraints on practice.
• Gender identity and adjustment in black, Hispanic, and white preadolescents.
• Glioblastoma.
• Hierarchy of iron uptake systems: Yfu and Yiu are functional in Yersinia pestis.
• Identification of critical amino acid residues in the plague biofilm Hms proteins.
• Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts.
• On-board Imaging - the Ipswich Experience.
• Oxidative damage to RNA in neurodegenerative diseases.
• Power in Numbers: Using EPINet Data to Promote Protective Policies for Healthcare Workers.
• Rasagiline: a review of its use in the management of Parkinson's disease.
• Rectus sheath hematoma: a series of unfortunate events.
• Road effects on abundance and fitness of Galápagos lava lizards (Microlophus albemarlensis).
• Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline.
• Selective reporting of pharmaceutical data leads major medical journals to change editorial policy.
• Small cell lung cancer: have we made any progress over the last 25 years?
• Spotlight on ramipril in the prevention of cardiovascular outcomes.
• Tacrolimus once-daily formulation : in the prophylaxis of transplant rejection in renal or liver allograft recipients.
• The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients.
• Vascular oxidative stress in Alzheimer disease.
• Walking in a city neighbourhood, paving the way.
• Work-related ladder fall fractures: identification and diagnosis validation using narrative text.
• You can make a difference.